ES2175925T3 - Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. - Google Patents

Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1.

Info

Publication number
ES2175925T3
ES2175925T3 ES99900012T ES99900012T ES2175925T3 ES 2175925 T3 ES2175925 T3 ES 2175925T3 ES 99900012 T ES99900012 T ES 99900012T ES 99900012 T ES99900012 T ES 99900012T ES 2175925 T3 ES2175925 T3 ES 2175925T3
Authority
ES
Spain
Prior art keywords
alkyl
heterocyclic
amino
independently selected
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99900012T
Other languages
English (en)
Inventor
Fumitaka Ito
Hiroshi Kondo
Hirohide Noguchi
Yoriko Ohashi
Tatsuya Yamagishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2175925T3 publication Critical patent/ES2175925T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

5 1. Un compuesto con la siguiente Fórmula: **fórmula** o las sales farmacéuticamente aceptables del mismo, en la que R 1 y R 2 son independientemente alquilo C1-C4; o R 1 y R 2 , junto con el átomo de carbono al que están unidos forman un grupo mono-, bi-, trio espirocíclico que tiene entre 6 y 13 átomos de carbono, en el que el grupo cíclico está opcionalmente sustituido con uno a cinco sustituyentes independientemente seleccionados entre alquilo C1-C4, alquileno C2-C4, alcoxi C1-C4, hidroxi, oxo, =CH2 y =CH-alquilo C1-C4; R 3 es alquilo C1-C7, alquenilo C2-C5, alquinilo C2-C5, fenil-alquilo-C1-C5, fenilo opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre úor, alquilo C1-C3 y alcoxi C1-C3, o un grupo heteroarilo seleccionado entre furilo, tienilo, pirrolilo y piridilo, en el que dicho grupo heteroarilo está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre halógeno, alquilo C1-C3 y alcoxiC1-C3, con la condición de que cuando ambos R 1 y R 2 son alquilo C1-C4, entonces R 3 es distinto a alquilo C1-C7, alquenilo C2-C5 y alquinilo C2-C5; R 4 se selecciona entre: 1) hidrógeno, 2) alquilo (C1-C8), cicloalquilo (C3-C7), alquenilo (C2-C8), alquinilo (C2-C8), alquilo (C1-C6)-Z-, alquilo (C1-C6)-Z-alquilo (C1-C6), cicloalquilo (C3-C7)-Z-alquilo (C1-C6), alquenilo (C2-C6)-Z-alquilo (C1-C6) o alquinilo (C2-C6)-Z-alquilo (C1-C6), opcionalmente mono o disustituido donde Z se selecciona entre O, S, SO, SO2, CO,CO2, OCO, NR, CONR y NRCO, donde R es hidrógeno o alquilo (C1-C6) y los sustituyentes a unirse al radical alquilo, alquenilo, alquinilo o cicloalquilo se seleccionan independientemente entre halógeno, hidroxi, carboxi, amino, monoo di-(alquil C1-C4)amino, hidrazino, azido, ureido, amidino y guanidino; o 3) arilo, heterocíclico, arilalquilo (C1-C5), heterocíclico alquilo (C1-C5), heterocíclico-heterocíclico alquilo (C1-C5); arilheterocíclico alquilo (C1-C5); heterocíclico-Z-alquilo (C1-C5), aril-Z-alquilo (C1C5), arilalquilo (C1-C5)-Z-alquilo (C1-C5) oheterocíclico alquilo (C1-C5)-Z-alquilo (C1-C5), opcionalmente mono o disustituido, en el que el grupo arilo se selecciona entre fenilo, naftilo, indanilo, (1,2,3,4)-tetrahidronaftilo, indenilo e isoindenilo; el grupo heterocíclico se selecciona entre piperidino, hexametilenimino, morfolino, tiamorfolino, pirrolidino, pirazolino, pirazolidino, pirazorilo, piperazinilo, furilo, tienilo, oxazolilo, tetrazolilo, tiazolilo, imidazolilo, imidazolinilo, pirazolilo, piridilo, pirimidinilo, pirrolilo, pirrolidinilo, quinolilo, tiofenilo, pirazinilo, piridazinilo, aziridinilo y azetidinilo; en el que Z se selecciona entre O, S, SO, SO2, CO,CO2, OCO, NR, CONR y NRCO, en el que R es hidrógeno o alquilo (C1-C6) y los sustituyentes a los que se une el radical arilo o heterocíclico se seleccionan independientemente entre halógeno, hidroxi, carboxi, alquilo (C1-C4), halo alquilo (C1-C4), alcoxi (C1-C4), alquilo (C1-C4)-CO-, alquil (C1-C4) amino-CO-, fenilo, bencilo, amino, monoo di(alquil C1-C4)amino, hidrazino, azido, ureido, amidino y guanidino; R 5 se selecciona independientemente entre halógeno, alquilo C1-C3, alcoxi C1-C3, alquil(C1-C3) sulfonilo, CF3, carboxi, hidroxi, amino, alquilamino, acilamino, arilcarbonilo, alquilcarbonilo e hidroxialquilo y n es 0,1, 2, 3ó 4.
ES99900012T 1998-01-19 1999-01-08 Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. Expired - Lifetime ES2175925T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB9800069 1998-01-19

Publications (1)

Publication Number Publication Date
ES2175925T3 true ES2175925T3 (es) 2002-11-16

Family

ID=11004651

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99900012T Expired - Lifetime ES2175925T3 (es) 1998-01-19 1999-01-08 Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1.

Country Status (30)

Country Link
US (1) US6423725B1 (es)
EP (1) EP1049689B1 (es)
JP (1) JP3342478B2 (es)
CN (1) CN1288464A (es)
AP (1) AP9901442A0 (es)
AR (1) AR014421A1 (es)
AT (1) ATE219772T1 (es)
AU (1) AU1679099A (es)
BG (1) BG104670A (es)
BR (1) BR9907104A (es)
CA (1) CA2317462C (es)
CO (1) CO4990962A1 (es)
DE (1) DE69901934T2 (es)
DK (1) DK1049689T3 (es)
EA (1) EA200000683A1 (es)
ES (1) ES2175925T3 (es)
GT (1) GT199900008A (es)
IL (1) IL137149A0 (es)
IS (1) IS5539A (es)
MA (1) MA26598A1 (es)
NO (1) NO20003671L (es)
OA (1) OA11445A (es)
PA (1) PA8467101A1 (es)
PE (1) PE20000166A1 (es)
PL (1) PL342046A1 (es)
PT (1) PT1049689E (es)
TN (1) TNSN99006A1 (es)
TR (1) TR200002090T2 (es)
WO (1) WO1999036421A1 (es)
ZA (1) ZA99314B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP0997464B1 (en) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
AU1185300A (en) * 1998-11-20 2000-06-13 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivatives
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
ES2223588T3 (es) 1999-10-13 2005-03-01 Banyu Pharmaceutical Co., Ltd. Derivados de imidazolidinona sustituidos.
JP2003524634A (ja) 1999-12-06 2003-08-19 ユーロ−セルティーク,エス.エイ. ノシセプチン受容体親和性を有するベンズイミダゾール化合物
JP3989247B2 (ja) 1999-12-06 2007-10-10 ユーロ−セルティーク エス.エイ. ノシセプチン受容体親和性を有するトリアゾスピロ化合物
HK1049799A1 (zh) 1999-12-06 2003-05-30 Euro-Celtique, S.A. 具有类鸦片受体亲和力的三级氨基化合物
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US6969712B2 (en) 2000-11-15 2005-11-29 Banyu Pharmaceutical Co., Ltd. Benzimidazole derivatives
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
CN1516584A (zh) 2001-04-18 2004-07-28 ŷ�����ǹɷ����޹�˾ 螺吡唑化合物
ATE410165T1 (de) 2001-04-18 2008-10-15 Euro Celtique Sa Nociceptin-analoga
ATE403431T1 (de) 2001-04-18 2008-08-15 Euro Celtique Sa Benzimidazolon-verbindungen
EP2033644A1 (en) 2001-04-18 2009-03-11 Euro-Celtique S.A. Spiroindene and spiroindane compounds
RU2268883C2 (ru) 2001-04-18 2006-01-27 Эро-Селтик, С.А. Аналоги ноницептина и фармацевтическая композиция на их основе
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
JP3896309B2 (ja) 2001-07-09 2007-03-22 ファイザー株式会社 プロテインキナーゼc阻害物質としてのピラゾロキノリノン誘導体
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
JP2005289816A (ja) * 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
ATE457299T1 (de) * 2002-11-12 2010-02-15 Gruenenthal Gmbh 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ
SA04250305B1 (ar) * 2003-09-25 2008-06-02 سولفاي فارماسوتيكالز بي . في مشتقات بنزيميدازولون cenzimidazolone وكينازولينون quinazolinone كمساعادات على مستقبلات ORL1 البشرية
AR045843A1 (es) * 2003-10-03 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
AR054816A1 (es) * 2005-07-13 2007-07-18 Banyu Pharma Co Ltd Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
US20090111778A1 (en) * 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス.エイ. カルシウムチャネルブロッカーとしての環状尿素化合物
GB0605786D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
GB0605784D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
CA2666630C (en) * 2006-10-16 2012-01-24 Mitsubishi Tanabe Pharma Corporation Agent for prophylaxis or treatment of alcohol dependence or drug dependence
EP2397477B1 (en) * 2007-01-16 2014-03-05 Purdue Pharma LP Heterocyclic-substituted piperidine compounds and the uses thereof
CN101622241B (zh) 2007-03-01 2013-05-22 田边三菱制药株式会社 苯并咪唑化合物及其医药用途
WO2009027820A2 (en) 2007-08-31 2009-03-05 Purdue Pharma L.P. Substituted-quinoxaline-type-piperidine compounds and the uses thereof
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
TW201016675A (en) 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
JP2013532149A (ja) * 2010-06-17 2013-08-15 ノバルティス アーゲー ピペリジニル置換1,3−ジヒドロ−ベンゾイミダゾール−2−イリデンアミン誘導体
EP2976077A4 (en) 2013-03-22 2016-11-30 Scripps Research Inst SUBSTITUTED BENZIMIDAZOLE AS NOCICEPTIN RECEPTOR MODULATORS
BR112019010719A2 (pt) * 2016-11-28 2019-10-01 Mitsubishi Tanabe Pharma Corp composição farmacêutica para tratar a dependência de cocaína ou prevenir a recaída da dependência de cocaína, métodos para tratar a dependência e para prevenir a recaída da dependência de cocaína de cocaína, uso de (r)-2-{3-[1-(5-metil-1,2,3,4-tetra-hidronaftalen-1-il)piperidina-4-il]-2,3-di-hidro-2-oxo-benzimidazol-1-il}-n-metilacetamida ou um sal farmaceuticamente aceitável do mesmo, e, (r)-2-{3-[1-(5-metil-1,2,3,4-tetra-hidronaftalen-1-il)piperidina-4-il]-2,3-di-hidro-2-oxo-benzimidazol-1-il}-n-metilacetamida ou um sal farmaceuticamente aceitável do mesmo.
WO2019141803A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
CN116496270B (zh) * 2022-01-27 2024-09-24 四川大学华西医院 一类4-氨基哌啶衍生物及其制备方法和用途
AU2025206007A1 (en) * 2024-01-05 2026-04-16 Yichang Humanwell Pharmaceutical Co., Ltd. Cyclohexyl-substituted piperidine derivative, pharmaceutical composition comprising same, and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3161645A (en) 1962-12-18 1964-12-15 Res Lab Dr C Janssen N V 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds
US3318900A (en) 1964-05-06 1967-05-09 Janssen Pharmaceutica Nv Derivatives of benzimidazolinyl piperidine
JPS58180481A (ja) 1982-04-15 1983-10-21 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
AT388731B (de) 1987-12-15 1989-08-25 Gerot Pharmazeutika Neue derivate von benzimidazol, ihre herstellung und verwendung
AU7478396A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine agonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DE69736776T2 (de) 1996-04-19 2007-01-18 Neurosearch A/S 1-(4-piperidyl)-benzimidazole mit neurotropher aktivität
CA2291094C (en) 1997-05-30 2008-02-26 Banyu Pharmaceutical Co., Ltd. 2-oxoimidazole derivative

Also Published As

Publication number Publication date
DE69901934T2 (de) 2002-11-07
AP9901442A0 (en) 1999-03-31
TNSN99006A1 (fr) 2005-11-10
OA11445A (en) 2004-04-30
MA26598A1 (fr) 2004-12-20
CA2317462C (en) 2005-09-13
DK1049689T3 (da) 2002-07-22
PL342046A1 (en) 2001-05-21
BR9907104A (pt) 2000-10-24
IL137149A0 (en) 2001-07-24
PE20000166A1 (es) 2000-03-07
ATE219772T1 (de) 2002-07-15
EP1049689B1 (en) 2002-06-26
NO20003671D0 (no) 2000-07-18
PA8467101A1 (es) 2000-09-29
EA200000683A1 (ru) 2000-12-25
JP3342478B2 (ja) 2002-11-11
CA2317462A1 (en) 1999-07-22
CN1288464A (zh) 2001-03-21
PT1049689E (pt) 2002-09-30
DE69901934D1 (de) 2002-08-01
GT199900008A (es) 2000-07-12
ZA99314B (en) 2000-07-18
BG104670A (en) 2001-05-31
NO20003671L (no) 2000-09-18
WO1999036421A1 (en) 1999-07-22
TR200002090T2 (tr) 2000-11-21
CO4990962A1 (es) 2000-12-26
IS5539A (is) 2000-06-16
AR014421A1 (es) 2001-02-28
EP1049689A1 (en) 2000-11-08
AU1679099A (en) 1999-08-02
US6423725B1 (en) 2002-07-23
JP2002509148A (ja) 2002-03-26

Similar Documents

Publication Publication Date Title
CO4990962A1 (es) Compuestos 4-(2-ceto-1-benzilimida-zolinil) piperidina como antagonistas del receptor orl1
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
CO5631432A2 (es) Derivados de n-[fenil(piepidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica
AR055051A1 (es) Compuestos de tiazol y oxazol y composiciones farmaceuticas que los contienen.
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
PE20020585A1 (es) Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona
AR045587A1 (es) Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
AR015770A1 (es) DERIVADOS DE ÁCIDO PIRIDIN-3-CARBOXíLICO uTILES COMO INTERMEDIARIOS EN LA PREPARACIoN DE PIRAZOLO PIRIMIDINONAS.
CO5670367A2 (es) Derivados de acido fenoxiacetico
ECSP088479A (es) Derivados de oxadiazol
NO20053647L (no) Pyrazolopyridinderivater
CR8468A (es) Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1
HN2005000030A (es) Derivados de sulfonamida para el tratamiento de enfermedades
RU2012143212A (ru) Способ лечения артрита
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
CO5611152A2 (es) Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
AR008168A1 (es) Compuestos etilamino arilamida aril substituidos de pirrolidinilo y pirrolinilo, composicion farmaceutica que lo contiene, compuesto util para susintesis, procedimiento para su preparacion
CO5601039A2 (es) Oxazolidinonas de indolona y derivados de las mismas
TW200633996A (en) N-[(4,5-diphenyl-3-alkyl-2-thienyl)methyl]amine derivatives, preparation thereof and therapeutic use thereof
CO5590858A2 (es) Composicion fungicida basada en un derivado de piridilmetilbenzamida e iprovalicarb
MY148980A (en) Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
PE20080206A1 (es) Derivados de aril y heteroaril-etil-acilguanidina como inhibidores de renina

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1049689

Country of ref document: ES